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Background: Osteoarthritis (OA) is the most common degenerative joint disease, of which the pathogenesis is
inadequately understood. Hypertrophy-like changes have been observed as part of the progression of OA. The aim
of the study was to develop and characterize a novel biomarker of chondrocytes hypertrophy and investigate how
this marker was associated with cartilage degradation and inflammation in patients with various degrees of OA.
Methods: A competitive ELISA, C-Col10, applying a well-characterized monoclonal antibody was developed as a
biomarker of chondrocyte hypertrophy through measurement of type X collagen (ColX). The levels of C-Col10, C2M
(matrix metalloproteinase-derived fragments of type II collagen) and hsCRP (high sensitive C-reactive protein) were
quantified by ELISAs in serum of 271 OA patients stratified by Kellgren-Lawrence (KL) score 0–4. Associations between
serum levels of the three biomarkers (log transformed) were analyzed by Pearson’s correlation and differences in C-Col10
levels between patients with high and low levels of inflammation measured by hsCRP were analyzed by ANOVA.
Results: We developed a C-Col10 assay measuring the C-terminus of ColX. We found significantly higher levels of ColX
in patients with KL score 2 compared to patients with no radiographic evidence of OA (KL0) (p = 0.04). Levels of ColX
were significantly elevated in OA patients with above normal hsCRP levels (p < 0.0001), as well as significantly correlated
with levels of C2M (r = 0.55, p < 0.0001), which suggested that chondrocyte hypertrophy was associated with inflammation
and cartilage degradation. There was no correlation between C2M and hsCRP. Age and BMI adjustment didn’t change the
results. Immuno-staining revealed that ColX was predominately located around the hypertrophic chondrocytes and the
clustered chondrocytes indicating that C-Col10 measures may be linked to cartilage hypertrophic changes.
Conclusions: We developed a novel assay, C-Col10, for measurement of chondrocyte hypertrophy and found its
levels significantly elevated in OA patients with KL score of 2, and also in OA patients with above normal hsCRP
levels. Concentration of C-Col10 strongly correlated with levels of C2M, a marker of cartilage destruction. The data
suggest that chondrocyte hypertrophy and subsequent collagen X fragmentation seem to be increased in a subset of
patients with inflammatory OA.
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Osteoarthritis (OA) is the most common joint disease,
which is characterized by cartilage damage and loss of
joint function. The high prevalence, with the accompany-
ing disabilities of OA results in a huge economic burden
on society [1]. However, the molecular mechanism of OA
disease remains partly understood and is more compli-
cated than expected. Not only the changes in extracellular
matrix (ECM) composition, but also changes in the me-
tabolism of chondrocytes contribute to the progression of
OA [2]. The events of chondrocytes hypertrophy differen-
tiation including matrix degradation, neo-vessels invasion
from subchondral bone and matrix calcification have been
observed in the progression of OA, which mimic the pro-
cesses during skeletal development by endochondral
ossification [3-6]. Runt-related transcription factor 2
(RUNX2), a transcription regulator of type X collagen,
has been reported to be involved in the development
of OA disease [7]. The critical role of hypertrophy
chondrocytes have been summarized in several good
reviews [8-10].
Type X collagen (ColX) is a well-established marker for
hypertrophic chondrocytes differentiation, which is a non-
fibrillar collagen consisting of three identical alpha 1
chains. Each chain has three domains: a short triple helix
domain flanked by a bigger globular domain (NC1 domain)
at the carboxyl end and a short non-collagenous domain
(NC2 domain) at the amino end [11]. The molecular
weight of each alpha 1 chain is 64 kDa of human ColX, of
which triple helix domain is 42 kDa [12]. ColX is suscep-
tible to interstitial collagenase and gelatinase cleavage at
two distinct sites within triple helix domain generating
fragments [13]. ColX is considered to be synthesized spe-
cifically by hypertrophic chondrocytes of growth plate dur-
ing the development of long bone [14]. Immunoelectron
microscopy shows that individual ColX molecules can rap-
idly assemble into a hexagonal lattice via carboxy-terminal
globular domains, which play the important role in modify-
ing the cartilage matrix for the subsequent bone formation
during endochondral ossification [15]. Besides the main-
tenance of tissue stiffness, several other roles have been
suggested, including regulating chondrocytes metabolism
and interacting with hypertrophic chondrocytes through
cell adhesion molecules such as integrins [16]. There is
increasing evidence that the expression of ColX is ele-
vated in human OA cartilage as a result of chondrocytes
hypertrophy and cartilage calcification [17-19]. The up-
regulation of ColX has been reported in experimental
animal OA models as well [20-23].
OA is thought to be a “non-inflammatory” joint disease
due to low level of inflammation in contrast to other joint
disease such as rheumatoid arthritis (RA). Despite that,
inflammation has indeed been considered to contribute to
the symptoms and progression of OA [24,25]. Circulatingmarkers of inflammation - such as C-reactive protein
(CRP), a common diagnostic marker for chronic inflamma-
tory disease such as RA - has been shown to be elevated in
subsets of OA patients as compared to a sample population
without disease [26]. Elevated serum CRP may reflect
inflammation in affected joints, like synovitis, which is
associated with clinical symptoms such as pain [27]. It was
reported by Cecil et al. that inflammation-induced chon-
drocytes hypertrophy is contributed significantly to the pro-
gression of OA [28]. Thus, it is interesting to investigate the
relationship between hypertrophy and inflammation in OA.
The aim of this study was to develop an immunoassay
(C-Col10) to determine the levels of ColX in blood and
to investigate the relationships between chondrocyte hyper-
trophy, cartilage degradation and systemic inflammation by
measuring three biomarkers in serum from 271 OA pa-
tients: C-Col10, C2M and high sensitive (hs) CRP. Serum
C2M measures circulating fragments of type II collagen, a
surrogate marker of cartilage degradation. C2M was found
to be significantly higher in patients with moderate/severe
OA compared to patients with mild OA or healthy age-
matched controls [29], as well as in patients with ankylos-
ing spondylitis (AS) compared to controls [30].
Methods
Materials
Materials and chemicals were purchased from Sigma-
Aldrich (Broendby, Denmark) or VWR (Roedovre,
Denmark) if not stated otherwise.
Serum samples from OA patients
Serum samples were retrieved from C4Pain study (n =
271 with Kellgren-Lawrence score ranging from 0–4). In
this study, the OA population was recruited based on in-
tensity of knee joint pain, ranging from 0 to 100 on a
Western Ontario and McMaster Universities Osteoarthritis
Index (WOMAC) pain scale. Two plain X-ray examina-
tions in standing position were performed. Serum was col-
lected upon overnight fasting prior to surgery or during
consultation. The study was approved by The Ethical Com-
mittee of Northern Jutland (VEK no.: N-20100094). It was
conducted according to the Principal of Good Clinical
Practice and according to the Declaration of Helsinki. All
patients provided written informed consent.
Development and characterization of anti-ColX monoclonal
antibody
A specific peptide, SFSGFLVAPM obtained from C-
terminus of NC1 domain of ColX was synthesized and
conjugated to maleimide-activated keyhole-limpet
hemocyanin (KLH, Pierce, Beijing, China) as immuno-
gen. The immunogens were used to immunize female,
seven-week-old Balb/C mice by repeating injections.
The monoclonal antibody was produced by standard
Table 1 Sequence alignment of the last 10 aa of NC-1
domain of ColX α1 chain in different species
Species Sequence Database
Homo sapiens1 SFSGFLVAPM GenBank:CAA46236.1
Mus musculus2 SFSGFLVAPM GenBank:CAA46237.1
Bos taurus3 SFSGFLVAPM NCBI: NP_777059.1
Rattus norvegicus4 SFSGFLVAPI GenBank: CAA10518.1
Canis lupus familiaris5 SFSGFLVAPM NCBI: XP_003639449.1
Equus caballus6 SFSGFLVAPM NCBI: XP_001504151.1
1Human; 2Mouse; 3Cattle; 4Rat; 5Dog; 6Horse.
Figure 1 Peptide specificity test. The peptide specificity was
evaluated by three synthetic peptides in inhibition ELISA: the selection
peptide (SFSGFLVAPM), the truncated peptide (SFSGFLVM) and the
non-sense peptide (DMDYLPRVPNQ). The OD signal was dramatically
inhibited by the selection peptide, but not the truncated peptide nor
the non-sense peptide.
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characterized by competitive ELISA by using the spe-
cific peptide (SFSGFLVAPM), the truncated peptide
(SFSGFLVA) without last 2 amino acids and the non-
sense peptide (DMDYLPRVPNQ).
Western Blotting of U2-OS cell lysates
Further characterization of ColX monoclonal antibody,
NB509-11G8, was conducted by western blotting with
cell lysates of human osteosarcoma cell line, U2-OS ex-
pressing type X collagen. The cell lysates were prepared
using fresh RIPA buffer (25 mM Tris–HCl pH7.6, 150 mM
NaCl, 1 Sodium deoxycholate acid and fresh EDTA-free
protease inhibitor cocktail tablet (Roche, USA)). U2-OS
lysates were separated in 4–12 Bis-Tris gradient gel and
electrically transferred to polyvinylidene fluoride (PVDF)
membrane. After blocking, the membrane was incubated
with 1 μg/ml NB509-11G8 antibody or X53 (positive
control for intact ColX) at 4°C overnight. To confirm the
specificity of bands, the peptide inhibition western blotting
was performed in parallel with adding 3 μg/ml selection
peptide or truncated peptide into NB509-11G8 antibody
solution, then immediately incubated with the membrane.
After incubation with goat anti-mouse secondary antibody
(1:5000) at RT (room temperature) for 2 hr, the membrane
was washed and detected using enhanced chemilumines-
cence (ECL) western blotting substrate (GE healthcare,
Denmark). The bands were visualized through exposure
to X-ray film.
To investigate the possibility of NB509-11G8 detecting
type X collagen fragments, the in vitro digestion of U2-OS
lysates was carried out by degradation of collagenase
(C6885, Sigma) with two concentrations, 50 μg/ml and
5 μg/ml. The cleavage reactions were carried out for 1 hr,
2 hr, 4 hr or overnight (20 ± 1 hr) at 37°C. These mixtures
were submitted to western blotting and detected by
NB509-11G8 antibody and X53.
Western blotting of human OA cartilage extracts
Cartilage biopsies were obtained from 3 OA patients
who underwent total knee arthroplasty. Proteins were
extracted with 1 ml 4 M guanidinium chloride (GuHCl)
containing 50 mM Sodium Acetate, 10 mM EDTA, 0.1 M
Hexanoic Acid, pH5.8 at 4°C for 48 hr. The extract was
separated from cartilage residue by centrifugation (800 g)
at 4°C for 10 min and stored at −70°C prior to use. Inhi-
bition western blotting as mentioned above was applied to
detect type X collagen in three human OA cartilage
extracts (human skeletal muscle extract used as negative
control from Biochain, USA).
Development and characterization of the C-Col10 ELISA
The competitive C-Col10 ELISA was developed with
optimal mix of buffer, incubation time, temperature andconcentrations of reagents. The final protocol was as fol-
lows: 100 μl biotinylated peptide was added to a strepta-
vidin pre-coated plate and incubated at 20°C for 30 min.
Next, the plate was washed 5 times with standard wash
buffer. 20 μl standards or samples together with 100 μl
peroxidase labeled antibody were added to the plate and
incubated at 4°C overnight with shaking. After that,
the wells were washed 5 times and 100 μl/well 3,3’,5,5’-
tetramethylbenzidine (TMB) was added and incubated in
the dark at 20°C for 15 min. Lastly, 100 μl/well stopping
solution (0.1 H2SO4) was added and the colorimetric re-
action was measured at 450 nm with reference at 650 nm.
Technical assay validation was done according to the
international guide.Biochemical markers
ColX, cartilage degradation and systemic inflammation
were quantified in serum of 271 OA patients by 3 assays:
C-Col10, C2M and hsCRP (Siemens 74701). C-Col10
assay was followed the protocol above mentioned, while
hsCRP assay was strictly followed the protocol recom-
mended in the kit manual. C2M ELISA assay was followed
Figure 2 Western blotting on U2-OS cell lysates. A. Lane 1 and 6: marker. Lane 2, 4 and 7: U2-OS cell lysates; Lane 3, 5 and 8: RIPA buffer. 5
bands have been identified in U2-OS cell lysates by NB509-11G8. Moreover, these bands can be completely blocked by the selection peptide, but
not the truncated peptide. B. U2-OS cell lysates in vitro digestion products detected by X53 on western blotting. Lane1: marker. Lane 2: U2-OS cell
lysates; Lane 3–6: U2-OS cell lysates incubated with 5 ug/ml collagenase for 1 hr, 2 hr, 4 hr or overnight. Lane7-10: U2-OS cell lysates incubated with
50 ug/ml collagenase for 1 hr, 2 hr, 4 hr or overnight. X53 only detected 64 kDa α1 chain. The intensity of this chain decreased with the incubation time
and the amount of collagenase. C. U2-OS cell lysates in vitro digestion products detected by NB509-11G8 on western blotting. Lane 1: U2-OS cell lysates;
Lane 2–5: U2-OS cell lysates incubated with 5 ug/ml collagenase for 1 hr, 2 hr, 4 hr and overnight. Lane6-9: U2-OS cell lysates incubated with
50 ug/ml collagenase for 1 hr, 2 hr, 4 hr or overnight. Lane10: marker. The degradation of ColX by collagenase exhibited a time- and dose-
dependent pattern.
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several studies [30,31].
In situ detection of ColX in human OA cartilage
Cartilage biopsies from 3 OA patients were taken from
OA patients undergoing total knee replacement surgery
at the Department of Orthopedics at Sygehus Vendsyssel,
Frederikshavn, Denmark. The retrieval of specimens
complied with international ethical guidelines for handling
human samples and patient information. All participants
signed an informed consent form and the study was
approved by Danish National Ethical Committees under the
Act on Research Ethics Review of Health Research Projects
(journal no. N-20110031).
The cartilage biopsies were fixed in formaldehyde, dec-
alcified with EDTA, and embedded in paraffin. Sections
were cut into 5 μm adjacent sections and melted at 60°C,
deparaffinized and hydrated. Endogenous Peroxidase
activity was blocked with H2O2 in 99 ethanol by incu-
bation at RT for 20 min. For C-Col10, antigen retrieval
was done by Pronase E (Roche) at 37°C for 15 min. ForC2M, citrate buffer pH6.0 at 60°C overnight was used
to unmask antigen. Unspecific protein binding was
blocked with 0.5 casein in TBS buffer at RT for 30 min.
Afterward, NB509- 11G8 antibody, the C2M antibody
or normal mouse IgG (negative control) were incubated
with sections at 4°C overnight. Immunoactivity was
detected by using peroxidase labeled secondary anti-
body and diminobenzidine (DAB, Dako, Denmark) as
chromogen. Sections were counter stained with Mayer’s
acidic hematoxylin for 12 sec. Pictures were taken with a
digital camera (Olympus C5050) on a microscope
(Olympus BX60).Statistics
Statistic analysis of correlation was performed using
GraphPad Prism@ version 5. Levels of the 3 biomarkers
in serum samples were shown as mean [95-CI]. One-
way ANOVA was applied when compare biomarker
levels. Correlations between levels of biomarkers were
done by Pearson’s test on log transformed data.
Figure 3 Western blotting on human OA cartilage extract. A. Lane1 and 8: human OA cartilage extract1; Lane 2 and 9: human OA cartilage
extract 2; Lane 3 and 10: human OA cartilage extract3; Lane 4 and 11: GuHCl extraction buffer. Lane 5 and 12: human skeletal muscle extract;
Lane 6: muscle extraction buffer. Lane 7: marker. Lane 1–7 was incubated with NB509-11G8, while Lane 8–12 was incubated with non-sense
mouse IgG. The same size of 17 kDa band was visualized in three cartilage extract, but not in the muscle extract. No any band was detected in
neither cartilage extract nor muscle extract by non-sense mouse IgG. B. Peptide inhibition western blotting on human OA cartilage extracts. Lane
5: marker; Lane 1and 6: human OA cartilage extract1; Lane 2 and 7: human OA cartilage extract2; Lane 3 and 8: human OA cartilage extract3. Lane
4 and 9: GuHCl extraction buffer. The 17 kDa bands in 3 human OA extracts were blocked by selected peptide, but not truncated peptide.
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The specificity of the monoclonal antibody NB509-11G8
The sequence alignment of species is shown in Table 1.
The signal of NB509-11G8 (IgG1, κ) was displaced by
increasing concentration of selection peptide (SFSGFL
VAPM), but neither by the truncated peptide (SFSGFL
VA) nor by the non-sense peptide (DMDYLPRVPNQ)
(Figure 1), indicating that NB509-11G8 specifically
recognized the unique C-terminus of NC1 domain.Detection of ColX by the monoclonal antibody NB509-11G8
in U2-OS cell lysates and human cartilage extracts
U2-OS is a widely used human osteo/chondroblast-like
cell line derived from malignant bone tumors with the
capacity to express ColX [32]. Commercial X53 antibody
recognized only intact α1 chain (Figure 2B, lane 2),
whereas NB509-11G8 detected five bands (Figure 2A): i)
a 17 kDa band, corresponding to a previously reported
band generated by intestinal collagenase (MMP-1) [13];
Table 2 Summary of technical performance for 3 biomarkers assays
C-Col10 (pg/ml) hsCRP (μg/ml) C2M (pg/ml)
Assay specifications
Slope of standard curve 1.23 n. a. 0.96
IC50, pg/ml 363 n. a. 440
Intra-assay CV% 4.19 n. a. 3.95
Inter-assay CV% 13.18 <5 9.88
Lower limit of detection 24 n. a. n. a.
Quantifiable range 40-7300 0.2-10 30-1700
C-Col10: C-terminus of ColX assay; C2M: MMP-derived collagen type II fragment assay; hsCRP: high sensitive CRP assay. n.a.: not available.
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helix domain; iii) a 64 kDa band representing the intact
α1 strand; iv) an unknown 76 kDa band, and v) an un-
known 120 kDa band. The difference in bands detected
by X53 and NB509-11G8 might be explained by the fact
that they target against different sequences. The epitope
of X53 has been suggested to recognize a pepsin-resistant
epitope overlapping collagenous domain and portion of
NC-1 domain. All bands were absent, when the selection
peptide was added into NB509-11G8 solution, indicating
that all bands carry the C-terminus of NC-1 domain.
The degradation of ColX by collagenase showed a time-
and dose- dependent pattern, which was demonstrated
using both X53 and NB509-11G8 (Figure 2B and 2C). The
α1 chain following digestion exhibited greatly reduced
intensity when stained by X53 (Figure 2B). Digestion with
5 μg/ml collagenase released more fragments detected by
NB509-11G8(Figure 2C, lane 2–4) than before treatment
(lane 1). The 120 kDa band became weaker over incuba-
tion time and completely disappeared after overnight incu-
bation, whereas a 32 kDa band was more clearly visible.
Meanwhile, 50 μg/ml collagenase aggressively degraded
ColX (lane 6–9). The 17 kDa band were unaffected by the
collagenase treatment.
A major 17 kDa-fragment was identified in three differ-
ent human OA cartilage extracts (Figure 3A), but not in
human skeletal muscle extract. No any band was detected








0 4/6 62.5 (57.3-67.7) 25.4 (23.7-27.0)
1 31/28 63.7 (61.6-65.8) 27.0 (26.0-28.1)
2 79/65 64.7 (63.5-65.9) 28.2 (27.5-28.8)
3 17/19 64.3 (61.9-66.7) 29.3 (27.4-31.2)
4 12/10 67.8 (64.4-71.2) 29.5 (27.8-31.2)
The data is shown as mean [95-CI]. C-Col10: C-terminus of ColX assay; C2M: MMP-d
KL score: Kellgren-Lawrence score. One-way ANOVA was applied to compare the m
considered statistically significant if P < 0.05 and significant level was presented as:the bands were completely blocked by the selection pep-
tide instead of the truncated peptide, demonstrating
the 17 kDa fragment contains the C-terminus of ColX
(Figure 3B).
The technical performance of the C-Col10 ELISA
A competitive ELISA was developed by applying the
NB509-11G8 monoclonal antibody. The technical perform-
ance of this ELISA is summarized in Table 2. The LLOD
was 24 pg/ml. The intra-assay CV was 4.19 and the
inter-assay CV was 13.2. The measurement range was
40–7300 pg/ml and the IC50 was 363 pg/ml. The dilution
recovery and peptide spiking recovery test in human serum
were 100 ± 20 within the measurement rang of the assay.
Biomarker levels in the C4Pain cohort
271 subjects were divided into 5 groups based on their KL
scores (Table 3). There was significant difference in the C-
Col10 levels between KL0 and KL2 (p = 0.04). The mean
value of C-Col10 in KL3 and KL 4 groups were 1.5 and
1.7 times higher but not statistically significant compared
to KL0 group respectively, which could be high variation
of individual C-Col10 levels in KL3 and KL4 groups.
There was a trend towards elevated C2M level with in-
creased KL score, but there was no significant difference
existing between any two groups. The hsCRP levels did
not show any correlation with the degree of KL score.
There was a significant correlation between C-Col10 andby KL score
C-Col10 hsCRP μg/ml C2M pg/ml
pg/ml P value
52 (24–80) n. a. 2.94 (−0.75-6.64) 287 (245–325)
65 (54–76) 0.11 2.12 (1.44-2.80) 299 (270–327)
86 (73–98) 0.04* 3.18 (2.26-4.10) 302 (283–321)
80 (60–101) 0.07 3.57 (1.35-5.79) 305 (264–346)
87 (47–128) 0.28 2.92 (1.90-3.94) 339 (271–406)
erived collagen type II fragment assay; hsCRP: high sensitive CRP assay.
ean C-Col10 levels of each KL group with the mean of KL 0 group. P value was
*.
Table 4 Correlations between serum levels of the 3
biomarkers
C-Col10 C2M
C-Col10 Correlation Coefficient n. a. 0.545
Significance Level P n. a. <0.0001
hsCRP Correlation Coefficient 0.233 0.071
Significance Level P <0.0001 0.2487
Pearson’s correlations were done on log transformed data. C-Col10: C-terminus
of ColX assay; C2M: MMP-derived collagen type II fragment assay; hsCRP: high
sensitive CRP assay.
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and C2M levels (r = 0.55, P <0.0001) (Table 4). No correl-
ation between C2M and hsCRP has been found. Age and
BMI adjustment did not change the significant correla-
tions. OA patients with above normal hsCRP (>5) levels
showed significantly increased C-Col10 levels (p < 0.0001)
(Figure 4).Immunolocalization of ColX in human OA cartilage by
immunohistochemistry
Cartilage biopsies including subchondral bone were
stained with Safranin O/ Fast Green and classified ac-
cording to severity of the cartilage damage (Figure 5A,
B, C). There was a clear immune-reactivity of ColX in
the deep zone and calcified cartilage matrix surround-
ing the hypertrophic chondrocytes in the mild OA
section (Figure 5D, G). Staining of ColX was observed
in the middle zone cartilage matrix in the moderate
OA section (Figure 5E, H). The obvious staining of
ColX was also observed in the matrix of clustered
chondrocytes close to the fibrillated surface in the
severe OA section (Figure 5F, I). C2M was observed in
all layers and consistently in 3 specimens (Figure 5J-O).
No obvious and specific staining was found in sections
incubated with normal mouse IgG (negative control,
Figure 5P-R).< 0.0001
Figure 4 Elevated C-Col10 levels in patients with above normal
hsCRP levels, 5 μg/ml. T-test was used on log transformed data to
determine the significant difference between these two groups.Discussion
In this study, we have developed and technically vali-
dated a novel and specific ELISA assay, C-Col10, which
can determine the level of ColX in serum. We found sig-
nificantly higher levels of ColX in patients with KL2
compared to patients with no radiographic sign of OA
(KL0). Although the mean of ColX were markedly higher
in KL3 and KL4 group than in KL0 group, these were not
significantly different. We observed a high variation in the
levels in these severe OA groups, which could indicate
that different subgroups exist and ColX not alone was
related to cartilage loss (hence joint space width) as
observed by radiography. This was further supported by
the significant correlation of between ColX and hsCRP
and C2M levels, suggesting that chondrocyte hypertrophy
was both associated with inflammation and cartilage
degradation. In addition, immunostaining using the same
monoclonal antibody as used in the C-Col10 assay
revealed that ColX was predominately located around the
hypertrophic chondrocytes located in the deep zone and
around the clustered chondrocytes located in the middle
and upper zone, indicating that C-Col10 measures were
associated with differential changes of chondrocytes rather
than solely degree of cartilage loss. To our knowledge, this
is the first study to provide evidence of correlations
between cartilage hypertrophy, inflammation and cartilage
matrix degradation measured in OA serum samples.
A limitation of this study is the unavailability of recom-
binant human ColX protein for characterization of the
antibody, NB509-11G8. Most commercial recombinant
ColX proteins are fused with a partner at C-terminus, like
6-histidine tag. However, NB509-11G8 is a C-terminus
specific antibody and the extra amino acids elongated at
the C-terminus would influence the binding to NB509-
11G8. Another limitation is the lack of detailed knowledge
on the structure and the mechanism of release of ColX
into circulation, thus there was no opportunity to make
comparable judgment on the results that we have achieved.
On the other hand our findings may add to the overall un-
derstanding of ColX in health and disease. Our findings
identified a 17 kDa fragment in both the U2-OS cell lysate
and human OA cartilage extract using the NB509-11G8
antibody, which align with the size of the fragment from
C-terminus to potential cleavage site at Gly479-Ile480 bond,
which has been identified in chick cartilage [13,33]. In
addition several other bands were identified indicating sev-
eral structural entities of ColX, as well as several cleavage
sites within the helical structure. The third limitation is
that besides articular chondrocytes, subchondarl bone and
osteophytes contribute to the serum measurement of ColX
as well. We only did immunohistochemistry on human
OA cartilage. We could image it will be quite interesting to
investigate the presence and expression pattern of ColX in
subchondral bone and osteophytes.
Figure 5 Immunostaining of C-Col10 and C2M in human OA knee cartilage sections. C-Col10 was observed in the deep zone around the
pre-hypertrophic chondrocytes in mild OA, and around chondrocyte clusters in severe OA, whereas C2M was observed in all layers and consistently in 3
OA cartilage sections. A, B, C: Safranin O/ Fast green histology staining, 4× magnification, scale bar 500 μm; D, E, F: stained with NB509-11G8 antibody,
4× magnification, scale bar 500 μm; G, H, I: stained with NB509-11G8 antibody, 10x magnification, scale bar 200 μm. J, K, L: stained with C2M antibody, scale
bar 500 μm;M, N, O: stained with C2M antibody, 10× magnification, scale bar 200 μm. P, Q, R: normal mouse IgG, negative control, scale bar 500 μm.
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hypertrophy, among which expression analysis of COL10A1
and MMP13 are probably the most widely used markers of
cartilage hypertrophy. However, synthesis of MMP13 can
be induced not only by hypertrophic chondrocytes, but also
by non-hypertrophic chondrocytes and other cells present
in the joint through inflammation and mechanical stress
[34,35]. Type X collagen may potentially be a more specific
marker of cartilage hypertrophy, as results on ColX seems
to be limited to cartilage in the human adult. We have herepresented data on the development and technically
validation of a robust competitive assay, C-Col10. The
level of C-Col10 was significantly correlated with level
of C2M, a surrogate marker of cartilage degradation,
which indicates a close relationship between chondro-
cytes hypertrophy and articular cartilage degradation.
The direct link has been confirmed by the immuno-
staining of C-Col10 and C2M on cartilage biopsies
taken from OA patients undergoing total knee re-
placement (TKR) surgery.
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disease, although it is evident that a subset of patients
does indeed have synovitis (i.e. chronic inflammation).
The hsCRP assay is used as standard diagnostic markers
in inflammatory joint diseases such as RA; however the
marker has limited usages in OA, since only a small
proportion of the patients have elevated levels, although
a few studies have shown hsCRP associated with clinical
severity in patients with knee or hip OA [36,37] and joint
pain [38]. In our study, significantly higher C-Col10 levels
were observed in patients with above normal hsCRP
(>5 μg/ml) levels. This association between hsCRP and
C-Col10 levels could indicate a causal relationship be-
tween inflammation and chondrocyte hypertrophy,
which has been suggested through the activity of
HIF-2α [39,40]. The interpretation of this relation is
consistent with previous studies that inflammatory factors,
like interleukin-8 [41], Interleukin-1βinduced S100A11
protein [42] can accelerate chondrocyte hypertrophy.
There are contradictory data regarding hypertrophic
chondrocyte in OA. Some publications have indicated
that terminal differentiation of chondrocytes into hyper-
trophy is associated with OA [6,43,44]. Therefore hyper-
trophy chondrocyte is considered as one of the hallmarks
in OA. In contrast, a study by Brew et al. demonstrated
that hypertrophy associated genes expression, like collagen
type X, was significantly down-regulated in OA cartilage
[45]. The discrepancy has indicated the complexity and
heterogeneity of the progression of OA disease, where dif-
ferent driving forces might be involved in. An earlier
ex vivo study by Chen-An et al. demonstrated that the
anti-resorptive drug, salmon calcitonin, was able to protect
cartilage from hypertrophy in articular cartilage explants
[46]. Our present study confirms and extends existing
reports that the phenotype of chondrocytes changing into
hypertrophy at least occurred in the subpopulation of
patients with OA. Thus, anti-hypertrophic differentiation
could be a critical factor considered for the future thera-
peutic OA drug development.
Conclusions
In conclusion, chondrocyte hypertrophy and subsequent
type X collagen seems to be increased in a subset of
patients with inflammatory OA. The increase of ColX
levels in serum possibly serve as a marker of local
chondrocyte hypertrophy and differentiation, and may
even aid in describing the progression of OA disease.
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